Quick Answer
BeOne Medicines Ltd. reported R&D Expense of $2.15 billion for fiscal year 2025.
BeOne Medicines Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.15B | +9.9% |
| 2024 | $1.95B | +9.8% |
| 2023 | $1.78B | +8.4% |
| 2022 | $1.64B | +12.4% |
| 2021 | $1.46B | +12.7% |
| 2020 | $1.29B | +39.6% |
| 2019 | $927.34M | +36.6% |
| 2018 | $679.00M | +152.4% |
| 2017 | $269.02M | +174.4% |
| 2016 | $98.03M | +68.3% |
| 2015 | $58.25M | +166.4% |
| 2014 | $21.86M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $523.66M | +5.5% | -0.2% |
| June 30, 2025 | $524.90M | +15.5% | +8.9% |
| March 31, 2025 | $481.89M | +4.6% | -2.9% |
| September 30, 2024 | $496.18M | +9.5% | +9.2% |
| June 30, 2024 | $454.47M | +7.5% | -1.3% |
| March 31, 2024 | $460.64M | +12.7% | +1.6% |
| September 30, 2023 | $453.26M | +6.3% | +7.2% |
| June 30, 2023 | $422.76M | +11.8% | +3.5% |
- BeOne Medicines Ltd. showed an increase of +9.9% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, BeOne Medicines Ltd.’s r&d expense has grown by 9715.5% (from $21.86 million to $2.15 billion).
- The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: